A Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MDI-2517 in Healthy Participants
Latest Information Update: 30 Oct 2025
At a glance
- Drugs MDI 2517 (Primary)
- Indications Fibrosis
- Focus Adverse reactions
- Sponsors MDI Therapeutics
Most Recent Events
- 30 Oct 2025 New trial record